Tevogen Bio Stock Price, News & Analysis

Tevogen (NASDAQ:TVGN) has expressed support for the White House's "Winning the Race: America's AI Action Plan" released on July 23, 2025. The company has developed PredicTcell™, an alpha version machine learning model, in partnership with Microsoft and Databricks.

The proprietary AI model is designed to significantly reduce target analysis time in immunotherapy research, potentially resulting in billions in cost savings for drug development. This aligns with the government's initiative to accelerate AI innovation and adoption in healthcare through domain-specific standards, regulatory sandboxes, and stakeholder convenings led by The National Institute of Standards and Technology.

The company, under CEO Ryan Saadi's leadership, emphasizes its commitment to developing scalable, ethical AI solutions to improve access to affordable advanced therapeutics.

Tevogen Bio Holdings (Nasdaq: TVGN) has received an international patent publication from WIPO for its AI technology that predicts immunologically active peptides. The patent (WO 2025/129197) covers Tevogen.AI's machine learning technology, powered by Microsoft and Databricks, designed to identify peptides with strong immune system interactions.

The technology aims to overcome traditional limitations by efficiently screening peptides, eliminating ineffective candidates, and continuously refining predictions using real-world data. This innovation is particularly significant for developing targeted therapies for cancers and infectious diseases, while considering diverse genetic factors like age, sex, race, and ethnicity.

Tevogen Bio (NASDAQ:TVGN) has signed a letter of intent to lease a 17,428-square-foot facility in New Jersey for cell therapy manufacturing operations. The facility, previously used by Pfizer and Cordis (former J&J division), will support GMP cell therapy manufacturing and complement Tevogen's growing pipeline powered by their PredicTcell™ AI-driven target discovery platform.

The lease term is expected to exceed five years, with occupancy beginning after final lease execution and necessary approvals. The strategic move aims to accelerate clinical development while maintaining cost efficiency and scalability. CEO Dr. Ryan Saadi indicated this facility will serve as a bridge while the company develops its own custom-built manufacturing facility.

Tevogen Bio (NASDAQ:TVGNW) has announced plans to expand its Tevogen.AI platform following the successful alpha launch of PredicTcell™, its AI-driven target discovery platform. The expansion aims to integrate patient data analysis capabilities, supported by Microsoft and Databricks.

The enhanced platform will focus on analyzing electronic health records and real-world patient data to identify potential clinical trial participants based on medical histories, demographics, and clinical profiles. This initiative is designed to support Tevogen's ExacTcell™ pipeline development by improving clinical trial efficiency and accelerating time-to-market for new therapeutic interventions.

The AI-driven approach aims to address key challenges in clinical trials, including patient identification and enrollment, while supporting Tevogen's mission to develop commercially viable, cost-effective personalized T cell therapies.

Tevogen.AI (NASDAQ:TVGNW), in collaboration with Microsoft and Databricks, has successfully developed the alpha version of its PredicTcell™ model, a groundbreaking AI platform for drug discovery. The model leverages machine learning and transformer architectures trained on terabyte-scale datasets of genetic and proteomic elements.

The platform has demonstrated significant efficiency improvements, reducing protein sequence analysis and peptide identification time from months to hours. Initially focused on virology datasets, Tevogen.AI plans to expand PredicTcell's application to oncology, potentially accelerating cancer immunotherapy development.

The company believes early adopters of AI-driven drug discovery could generate billions in revenue, while the technology could lead to substantial cost savings across the healthcare system by streamlining early-stage drug discovery and reducing wet lab dependency.

Tevogen Bio (NASDAQ:TVGN) has announced the completion and opening of its expanded corporate headquarters in Warren, New Jersey. The notable aspect of this expansion is that the build-out and first-year operating costs were personally funded by CEO Ryan Saadi, M.D., M.P.H., incurring no expenses for the company or shareholders.

The new facility has more than doubled the company's previous footprint and consolidates multiple teams including research, regulatory affairs, and the growing Tevogen.AI initiative under one roof. The expansion was completed ahead of schedule, and the company plans to host a formal ribbon-cutting ceremony with local officials, employees, and community partners.

Tevogen Bio Holdings (NASDAQ: TVGN) announced that CEO Ryan Saadi has made a personal contribution of $500,000 towards the build-out and first-year operating costs of the company's new corporate headquarters in Warren, New Jersey.

The new facility significantly expands Tevogen's operational capacity, more than doubling its previous footprint. It will centralize various teams including research, regulatory affairs, and the Tevogen.AI initiative. The facility features dedicated collaboration spaces for data scientists and engineers working on the company's proprietary PredicTcell™ and AdapTcell™ AI platforms.

According to CFO Kirti Desai, this investment demonstrates leadership's commitment to the company's long-term vision of developing accessible, affordable cell therapies while maintaining capital discipline.

Tevogen Bio (TVGN) has announced progress in developing a cytotoxic T lymphocyte (CTL) therapy targeting EBV-associated lymphomas. The company is utilizing its proprietary ExacTcell™ technology and artificial intelligence through Tevogen.AI to identify and validate EBV peptides for potential clinical trials. The R&D team is conducting confirmation studies on CTL responses to selected viral peptides, while leveraging AI to accelerate the identification of immunologically active targets across the EBV genome. Chief Scientific Officer Neal Flomenberg highlighted the potential of targeting EBV proteins with specific CTLs as a promising research direction for treating EBV-driven cancers. The company is currently in the preclinical evaluation phase and plans to provide further updates as research progresses.

Tevogen (TVGN) has announced the expansion of its corporate headquarters in Warren, New Jersey, effectively doubling its footprint. The expanded facility will centralize various operations including executive leadership, regulatory affairs, corporate strategy, and R&D teams previously located in Philadelphia. The headquarters will house Tevogen.AI and Generics & Biosimilars initiatives, with dedicated spaces for data scientists and engineers working on proprietary AdapTcell and PredicTcell algorithms. The company, which started as a biotech firm, is evolving into three main divisions: Tevogen Bio, Tevogen.AI, and Tevogen Generics & Biosimilars. The company projects cumulative revenues of $10-14 billion for Tevogen Oncology and $18-22 billion for Tevogen Specialty Care, with company assets previously valued at $10 billion. The expansion aims to enhance collaboration and operational efficiency while supporting potential new business units.